Registries and collaborative studies for primary ciliary dyskinesia in Europe. by Ardura-Garcia, Cristina et al.
Registries and collaborative studies for
primary ciliary dyskinesia in Europe
Cristina Ardura-Garcia 1,2, Myrofora Goutaki 1,2,3, Siobhán B. Carr 4,5,
Suzanne Crowley6,7, Florian S. Halbeisen 1,8, Kim G. Nielsen9,10,
Petra Pennekamp11,12, Johanna Raidt11,12, Guillaume Thouvenin 13,14,15,
Panayiotis K. Yiallouros16,17, Heymut Omran11,12 and Claudia E. Kuehni 1,2,3
Affiliations: 1Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. 2On behalf of
the iPCD Cohort, Bern, Switzerland. 3Paediatric Respiratory Medicine, Children’s University Hospital of Bern,
University of Bern, Bern, Switzerland. 4Primary Ciliary Dyskinesia Centre, Dept of Paediatric Respiratory
Medicine, Imperial College and Royal Brompton Hospital, London, UK. 5On behalf of the English Paediatric
PCD Management Service, London, UK. 6Paediatric Dept of Allergy and Lung Diseases, Oslo University
Hospital, Oslo, Norway. 7On behalf of the Norwegian PCD Registry, Oslo, Norway. 8On behalf of the Swiss PCD
Registry, Bern, Switzerland. 9Danish PCD Centre Copenhagen, Paediatric Pulmonary Service, Copenhagen
University Hospital, Copenhagen, Denmark. 10On behalf of the Danish PCD Registry, Copenhagen, Denmark.
11Dept of General Pediatrics, University Hospital Muenster, Muenster, Germany. 12On behalf of the
International PCD Registry Team, Muenster, Germany. 13Service de Pneumologie Pédiatrique, Hôpital
Trousseau AP-HP, Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, Paris, France.
14Inserm UMR S 933 RaDiCo-PCD, Paris, France. 15On behalf of the French RaDiCo-PCD Cohort, Paris,
France. 16Respiratory Physiology Laboratory, Medical School, University of Cyprus, Nicosia, Cyprus. 17On
behalf of the Cyprus PCD Registry, Nicosia, Cyprus.
Correspondence: Claudia E. Kuehni, Institute of Social and Preventive Medicine, University of Bern,
Mittelstrasse 43, 3012 Bern, Switzerland. E-mail: claudia.kuehni@ispm.unibe.ch
ABSTRACT Primary ciliary dyskinesia (PCD) is a rare inherited disease characterised by malfunctioning
cilia leading to a heterogeneous clinical phenotype with many organ systems affected. There is a lack of
data on clinical presentation, prognosis and effectiveness of treatments, making it mandatory to improve
the scientific evidence base.
This article reviews the data resources that are available in Europe for clinical and epidemiological
research in PCD, namely established national PCD registries and national cohort studies, plus two large
collaborative efforts (the international PCD (iPCD) Cohort and the International PCD Registry), and
discusses their strengths, limitations and perspectives.
Denmark, Cyprus, Norway and Switzerland have national population-based registries, while England
and France conduct multicentre cohort studies. Based on the data contained in these registries, the
prevalence of diagnosed PCD is 3–7 per 100000 in children and 0.2–6 per 100000 in adults. All registries,
together with other studies from Europe and beyond, contribute to the iPCD Cohort, a collaborative study
including data from over 4000 PCD patients, and to the International PCD Registry, which is part of the
ERN (European Reference Network)-LUNG network.
This rich resource of readily available, standardised and contemporaneous data will allow obtaining fast
answers to emerging clinical and research questions in PCD.
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Introduction
Primary ciliary dyskinesia (PCD) is a rare, genetic, multiorgan disease characterised by dysfunction of
motile cilia [1]. The main clinical manifestations are in the upper and lower respiratory tract with chronic
rhinosinusitis, recurrent otitis media, chronic wet cough and bronchiectasis, but other organs can be
affected [2–5]. About 50% of patients have situs inversus or situs ambiguous, with manifold variations of
left–right asymmetry and a large range of congenital heart defects [6–8]. Most men and some women with
PCD are infertile [9–11], and involvement of the central nervous system, olfactory system, inner ear,
kidneys and retina has been reported [12]. The clinical phenotype is highly variable [13, 14], partly
because of the numerous affected genes that lead to a variety of ultrastructural and functional defects.
Prevalence has been estimated as 1 per 10000 or 1 per 20000, but can be higher in consanguineous
societies [15–17]. Although symptoms usually start in the neonatal period, PCD is often diagnosed
late and many patients remain undiagnosed [15, 18–20]. Research in PCD has mostly focused on genetic
and diagnostic issues; publications on clinical presentation, natural history, prognostic factors and
treatments are limited. Publications have typically included few patients from specialised centres, lacked
statistical power and precision, and might not be representative for the average patient. Clinical
information has come mostly from retrospective chart reviews, is of limited quality and is not comparable
across studies [21].
Applied clinical research aims to continuously generate new knowledge to inform patient and clinician
decision making. For rare diseases such as PCD, there are many obstacles to clinical research. Adequate
sample size is a key limitation, further aggravated by the phenotypic heterogeneity and age-related
variability in presentation. While most patients are seen regularly in specialist clinics, with detailed annual
reviews, the documentation of these visits in hospital records is not standardised and varies even within
institutions. Relevant information is often missing and it remains unclear if missing aspects were not
investigated or if results were normal. Lastly, retrospective chart reviews are costly and time consuming. To
obtain high-quality clinical data on rare diseases, it is essential that studies are population based, i.e.
include all PCD patients living in a region, and provide real-time, standardised prospective data in a
shareable format, as a basis for collaborative observational research and as a sampling frame for nested
interventional studies. Patient organisations and rare disease specialists have both emphasised the
importance of registries [22, 23].
This review describes national and international registries and cohort studies for patients with PCD in
Europe, discusses their strengths and limitations, shows how they collaborate, and explains what they have
achieved.
National PCD registries or cohort studies in Europe
This section describes established national registries or cohort studies, which in August 2019 were:
1) population based, i.e. aiming to include every patient living in a defined catchment area, thus being
representative and allowing assessment of incidence; 2) based in Europe; 3) long-term initiatives
continuously including new patients without a foreseen end; 4) following patients over time to assess
disease course and outcomes; and 5) already established and recruiting patients.
For practical reasons we excluded registries from other regions of the world; those which were in the
planning stage but not yet functional; single-centre hospital-based studies and projects which were
cross-sectional or of limited duration; and those that collected opportunistic clinical data.
We identified the registries presented in discussion with the European PCD research community, which
has collaborated closely for years in the PCD Task Forces of the European Respiratory Society (ERS) [15,
24–27], the European Union’s Seventh Framework Programme (EU FP7) project BESTCILIA (Better
Experimental Screening and Treatment for Primary Ciliary Dyskinesia; www.bestcilia.eu) and the
BEAT-PCD (Better Experimental Approaches to Treat PCD; www.beatpcd.org) COST Action network [28, 29].
Details are presented in tables 1–3. We calculated prevalence of PCD by age group as number of
diagnosed PCD patients of a certain age group divided by the population counts of the same age group
from national statistics. Figure 1 shows the geographic location of the registries and their contribution to
international registries. Denmark, Cyprus, Switzerland and Norway have national population-based
registries, while England and France have collaborative studies with longitudinal data from all designated
PCD specialist services in the countries. Although not strictly population based, it is assumed that they
include most paediatric patients that are diagnosed in the two countries.
Danish PCD Registry
The Danish PCD Registry, founded in 2006, is hosted by the Danish PCD Centre (Copenhagen, Denmark)
and governed by the head of the service. The registry is national and includes all patients diagnosed with
PCD in Denmark since 1976. Patients are identified during diagnostic work-up after referral from other
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departments across the country (primarily from paediatrics, adult pulmonology, ear, nose and throat
(ENT), cardiology, and neonatology) and occasionally from abroad (Sweden and Norway), although the
latter are not followed-up after diagnosis and are not included in the counts on prevalence. The registry
collects diagnostic information from several years of repeated testing and longitudinal lung function tests
(more than 6000 tests). Clinical data are available by searching the EPIC electronic patient records. Data
TABLE 1 Primary ciliary dyskinesia (PCD) registries or cohort studies in Europe with national or near-national coverage:
characteristics and patient identification
Characteristics Inclusion criteria and
informed consent
Patient identification Funding Host institution
Danish PCD
Registry
National
(Denmark),
population based.
Founded 2006.
Inhabitants of
Denmark with definite,
highly likely or
suspected PCD.
Written informed
consent needed.
Passive, patients who are
referred to the national
PCD centre for
diagnostic work-up or
clinical management.
Hospital based, but
various funds have
supported
part-time
management.
Paediatric Pulmonary
Service, Dept of Paediatrics
and Adolescent Medicine,
Copenhagen University
Hospital, Rigshospitalet,
Copenhagen, Denmark.
www.dblc.dk
Cyprus PCD
Registry
National (Cyprus),
population based.
Founded 2013.
Inhabitants of Cyprus
and neighbouring
countries diagnosed
or followed-up in
Cyprus. Written
informed consent
needed.
Passive, patients who are
referred to the national
PCD centre for
diagnostic work-up or
clinical management.
National research
funding (Cyprus
Research
Promotion
Foundation).
Medical School, University
of Cyprus, Nicosia, Cyprus.
www.ucy.ac.cy/medical
Swiss PCD
Registry
National
(Switzerland),
population based.
Founded 2013.
Inhabitants of
Switzerland with
definite, highly likely
or suspected PCD.
Written informed
consent needed.
Active, by contacting
regularly all specialists
(paediatric and adult
pulmonologists, ENT
physicians, and fertility
specialists) and the
national patient
organisation.
Swiss National
Science
Foundation,
cantonal lung
leagues,
Foundation Milena
Carvajal.
Institute of Social and
Preventive Medicine,
University of Bern, Bern,
Switzerland.
www.ispm.ch
Norwegian PCD
Registry
National
(Norway),
population based.
Founded 2015.
Inhabitants of Norway
with definite or highly
likely PCD. Baseline
data without informed
consent; written
informed consent
needed to share data.
Passive, by inclusion of
patients referred with
suspected PCD. Active
from September 2019, by
contacting regularly all
specialists (paediatric
and adult
pulmonologists, ENT
physicians, and fertility
specialists).
National Advisory
Unit on Rare
Diseases.
Norwegian
Resource Centre
for Cystic Fibrosis.
Norwegian Resource Centre
for Cystic Fibrosis, Oslo,
Norway.
www.oslo-
universitetssykehus.no/nscf
English
Paediatric
PCD
Management
Service
National
(England), clinical
cohort. Founded
2012.
Inhabitants of
England, aged
0–17 years with
definite or highly likely
PCD. Written informed
consent needed.
Through the National
PCD Diagnostic Service,
comprised of three
centres.#
National Health
Service (NHS)
England.
National PCD Service; each
centre is owner of their
patients’ data.#
French
RaDiCo-PCD
Cohort
National (France),
clinical cohort.
Founded 2017.
Inhabitants of France
with definite PCD.
Written informed
consent needed.
Active, by contacting
regularly all specialists
(paediatric and adult
pulmonologists, ENT
physicians, and fertility
specialists) and the
national patient
organisation.
French National
Research Agency
under the specific
programme
“Investments for
the Future”.
Inserm UMR S 933
RaDiCo-PCD, Paris, France.
www.radico.fr/fr/connaitre-
radico/nos-cohortes-et-
autres-programmes-
associes/80-radico/147-
cohorte-radico-pcd
ENT: ear, nose and throat. #: University Hospital Southampton NHS Foundation Trust, Southampton, UK/Royal Brompton and Harefield
Foundation Trust, London, UK; University Hospitals of Leicester NHS Trust, Leicester, UK/Birmingham Children’s Hospital, Birmingham, UK;
Leeds Teaching Hospitals NHS Trust, Leeds, UK/Bradford Teaching Hospitals NHS Trust, Bradford, UK.
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are contributed to the international PCD (iPCD) Cohort [30–35] and the International PCD Registry [36],
and have led to many publications [37–49]. Currently, the registry includes 136 alive Danish residents
(49 aged <20 years, 61 aged 20–39 years and 26 aged ⩾40 years). Prevalence of PCD varies from 3.8 per
100000 in <20 year olds, 4.2 per 100000 in 20–39 year olds to 0.9 per 100000 in ⩾40 year olds.
Cyprus PCD Registry
The Cyprus PCD Registry, founded in 2013, is hosted by the Medical School of the University of Cyprus
(Nicosia, Cyprus). It is population based, and includes all patients with PCD who live in Cyprus or
neighbouring countries and have been diagnosed or followed-up in Cyprus. Patients are referred by
attending physicians at the single national PCD centre at Archbishop Makarios III Hospital in Nicosia and
the data entered in the registry are collected there. Data include demographics, diagnostic information,
genotyping and regular clinical follow-up information. Cyprus contributes to the iPCD Cohort [30–35, 50]
and the International PCD Registry [36], and has published extensively [51, 52]. Currently, the registry
contains data from 51 patients of whom 44 reside in Cyprus (14 aged <20 years, 16 aged 20–39 years and
14 aged ⩾40 years). Prevalence of diagnosed cases residing in Cyprus is 7.4 per 100000 in <20 year olds,
5.9 per 100000 in 20–39 year olds and 3.5 per 100000 in ⩾40 year olds.
Swiss PCD Registry
The Swiss PCD Registry, founded in 2013, is hosted by the University of Bern (Bern, Switzerland) and
governed by a national advisory board including all physicians who register patients [53]. It is population
based, aiming to include all patients with PCD living in Switzerland, and is registered at ClinicalTrials.gov
with identifier number NCT03606200. Patients are identified actively by regular contacts with physicians
of all specialities likely to see PCD patients (paediatric and adult pulmonologists, ENT physicians, fertility
specialists, cardiologists and neonatologists). The registry collects diagnostic data, clinical data from
encounter records, linked routine data (from birth, mortality, census and hospital statistics) and
patient-reported information from questionnaire surveys. It has contributed to several publications of the
iPCD Cohort [30–35, 50] and the International PCD Registry [36]. Currently, the registry includes 139
patients (53 aged <20 years, 49 aged 20–39 years and 37 aged ⩾40 years). Prevalence of diagnosed cases
varies from 3.1 per 100000 in <20 year olds, 2.2 per 100000 in 20–39 year olds to 0.8 per 100000 in
⩾40 year olds.
Norwegian PCD Registry
The Norwegian PCD Registry, founded in 2015, is hosted by the Norwegian Resource Centre for Cystic
Fibrosis (Oslo, Norway) and governed by an advisory board that includes physicians who contribute
patients. It is population based, aiming to include all patients with PCD living in Norway. Patients are
identified following referral for confirmation of diagnosis and there is planned active recruitment from late
2019 by direct contact with physicians of all specialities likely to see PCD patients. Data include diagnostic
information and regular follow-up data. Registry data can be linked to routine national statistical data and
to Norwegian neonatal and congenital heart disease registries. Data are contributed to the iPCD Cohort
[30–34, 50] and the International PCD Registry. Currently, the registry includes 91 patients (63 aged
TABLE 2 Primary ciliary dyskinesia (PCD) population-based registries in Europe with national or near-national coverage:
number of patients diagnosed and registered, and estimated prevalence#
Resident patients diagnosed with
PCD (2019) n
Total inhabitants in catchment area n Proportion of patients per 100000
inhabitants n
Total 0–19
years
20–39
years
⩾40
years
Total 0–19
years
20–39
years
⩾40
years
Total 0–19
years
20–39
years
⩾40
years
Danish PCD
Registry
136 49 61 26 5814461 1296896 1467759 3049806 2.3 3.8 4.2 0.9
Cyprus PCD
Registry
44 14 16 14 864236 189491 273657 401088 5.1 7.4 5.9 3.5
Swiss PCD
Registry
139 53 49 37 8419550 1691466 2250555 4477529 1.7 3.1 2.2 0.8
Norwegian PCD
Registry
91 63 24 4 5295619 1260893 1422329 2612397 1.7 5.0 1.7 0.2
#: prevalence was estimated by dividing the number of resident patients diagnosed with PCD by the total inhabitants in the catchment area, for
each category and the total.
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<20 years, 24 aged 20–39 years and four aged ⩾40 years). Prevalence of diagnosed cases varies from 5.0
per 100000 in <20 year olds, 1.7 per 100000 in 20–39 year olds to 0.2 per 100000 in ⩾40 year olds.
English Paediatric PCD Management Service
The English Paediatric PCD Management Service was commissioned by the National Health Service (NHS)
England in 2012 to complement the existing diagnostic service [54]. Patients are identified by the National
PCD Diagnostic Service, established in 2006 [55]. Children with a confirmed or “highly likely” diagnosis [26]
following testing receive annual review assessments in one of four PCD management centres (Leeds, Leicester,
London or Southampton) from a specialist PCD multidisciplinary team following a standardised service
specification. The service collects diagnostic information, annual clinical assessments (symptoms and
examinations), investigations (microbiology, spirometry, audiology, etc.) and information on treatments,
contributes to the iPCD Cohort [30–35, 50] and the International PCD Registry [36], and has published
extensively [19, 56–74]. Currently, the service includes 396 children, of a median age of 9.8 years, 53% males,
the majority being white British (37%) or Pakistani/British Pakistani (36%). A parallel nationally commissioned
adult service will start in 2020. Prevalence of diagnosed cases in the paediatric population is 2.7 per 100000.
TABLE 3 Primary ciliary dyskinesia (PCD) registries or cohort studies in Europe with national or near-national coverage: data
collection and contribution
Danish PCD
Registry
Cyprus PCD
Registry
Swiss PCD
Registry
Norwegian
PCD Registry
English Paediatric
PCD Management
Service
French
RaDiCo-PCD
Cohort
Collection of baseline data
Extraction from patient records ✓ ✓ ✓ ✓ ✓
Results of diagnostic tests
from national PCD service
✓ ✓ ✓ ✓
Standardised form
(FOLLOW-PCD) completed
prospectively during visits
✓ (Oct 2019) ✓ ( Jan 2004) ✓ (Oct 2019) ✓ (Oct 2019) ✓
Collection of follow-up data
Periodic data collection from
patient records
✓ ✓ ✓ ✓ ✓
Annual or 3-monthly review
assessments
✓ ✓ ✓ ✓
Standardised follow-up form
(FOLLOW-PCD)
✓ (Oct 2019) ✓ ✓ (Oct 2019) ✓
Questionnaire to patients ✓ (Oct 2019) ✓ (Oct 2019) ✓ (2020)
Type of data collected
Diagnostic information ✓ ✓ ✓ ✓ ✓ ✓
Clinical examinations ✓ ✓ ✓ ✓ ✓ ✓
Lung function tests ✓ ✓ ✓ ✓ ✓ ✓
Audiology ✓ ✓ ✓ ✓ ✓
Imaging ✓ ✓ ✓ ✓ ✓ ✓
Microbiological results ✓ ✓ ✓ ✓ ✓ ✓
Blood tests (e.g. liver function,
immune profiling)
✓ ✓ ✓
Medical and surgical
treatments
✓ ✓ ✓ ✓ ✓ ✓
Patient-reported data ✓ (Oct 2019) ✓ ✓ ✓ ✓ ✓
Annual QOL-PCD questionnaire ✓ (Oct 2019) ✓ (Oct 2019) ✓ (2020) ✓ ✓
National patient surveys ✓
Linkage with routine statistics
National mortality registry On request ✓ ✓
National birth/neonatal registry On request ✓ ✓
Census data On request ✓
Hospital episode statistics On request ✓ (planned) On request
Congenital heart disease registry ✓ On request
Contributes to
iPCD Cohort ✓ ✓ ✓ ✓ ✓ ✓
International PCD Registry
National Rare Disease Registry
✓ ✓ ✓
✓
✓ (Sept 2019) ✓ ✓
✓
QOL: quality of life.
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French RaDiCo-PCD Cohort
The French RaDiCo-PCD Cohort was founded in 2017 with the Research National Agency as a sponsor,
under the authority of the French Minister of Higher Education, Research and Innovation, and sustained
by the French National Rare Lung Disease Network. The cohort is hosted at the French National Institute
of Health and Medical Research (Institut National de la Santé et de la Recherche Médicale, Inserm, Paris,
Standardised retrospective database
FOLLOW-PCD prospective database
Argentina, Australia, Belgium, Canada,
Colombia, Cyprus, Czech Republic,
Denmark, France, Germany, Greece,
Israel, Italy, Netherlands, Norway,
Poland, Serbia, Spain, Switzerland,
Turkey, UK, USA
Austria, Belgium, Canada, Cyprus,
Denmark, France, Greece,
Germany, Italy, Netherlands,
Norway, Slovakia, Spain,
Switzerland, Turkey, UK, USA
iPCD Cohort
International PCD Registry
English
Paediatric
PCD
Management
Service
French
RaDiCo-PCD
Cohort
Swiss
PCD
Registry
Danish
PCD
Registry
Norwegian
PCD
Registry
Cyprus
PCD
Registry
FIGURE 1 Countries in Europe with established national population-based registries or multicentre cohort
studies and data flow between them and the international primary ciliary dyskinesia (iPCD) Cohort and the
International PCD Registry. Yellow ovals: clinical cohorts; green ovals: population-based registries; black
continuous lines: data contribution; black dashed lines: data sharing and collaborations; black stars: other
European countries that contribute data to the International PCD Registry; black circles: other European
countries that contribute data to the iPCD Cohort.
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France) (UMR S 933 RaDiCo), and is governed by a multidisciplinary board of physicians, researchers,
patients and experts in organisation and information systems. The main goal of RaDiCo-PCD is to
identify factors that predict disease severity in paediatric and adult PCD patients with well-established
diagnosis, followed in certified Rare Lung Disease centres [21, 75, 76]. It collects diagnostic information
and data from regular follow-ups. RaDiCo-PCD contributes to the iPCD Cohort [30–32, 34, 35], and has
reported on sino-nasal disease and fertility [9, 77, 78]. Currently, RaDiCo-PCD includes 185 patients (80
aged <20 years, 66 aged 20–39 years and 39 aged ⩾40 years). Prevalence of diagnosed cases varies from 0.6
per 100000 in <20 year olds, 0.4 per 100000 in 20–39 year olds to 0.1 per 100000 in ⩾40 year olds, as it is
a very new cohort, but increases rapidly with several new cases diagnosed or recruited each year.
Others
Several other countries in Europe have cross-sectional or longitudinal datasets on PCD patients treated in
specialised centres, without having a national registry or cohort study. These include Belgium, Italy and
the Netherlands. Most of these contribute either to the iPCD Cohort or the International PCD Registry, or
both. As they are not population based, however, data cannot be used to estimate incidence or prevalence
and it is unclear if they are representative for all patients in the respective country.
Collaborative studies: the iPCD Cohort and the International PCD Registry
The two large collaborative studies were both set up in BESTCILIA (2013–2016) in the EU FP7. Work
package 1 of BESTCILIA assembled available datasets on PCD in a retrospective international cohort
study, the iPCD Cohort [31], and work package 2 set up a prospective International PCD Registry [36].
Both datasets were further expanded through the COST Action BEAT-PCD into large, still growing
datasets [25, 28, 29]. They have different strengths and limitations, and the datasets are overlapping
because many centres contribute to both initiatives (table 4).
The iPCD Cohort
The iPCD Cohort is hosted by the University of Bern and governed by an international advisory board
including representatives from all contributing centres [31]. It aims to answer questions on clinical
presentation, severity, prognosis and treatments in patients with PCD. The iPCD Cohort was originally set
up as a retrospective international cohort, combining existing datasets on patients with PCD, but now also
collects prospective follow-up information. Since 2019 the iPCD Cohort has been linked with
FOLLOW-PCD, the standardised clinical form for documenting patient encounters in PCD clinics [79].
Eligible datasets and centres were initially identified by a systematic literature search for studies describing
clinical manifestations in patients with PCD [80], through personal contacts from the ERS PCD Task
Force (2006–2009) [15, 27] and from the BEAT-PCD network. New centres that wish to contribute data
can always join.
The iPCD Cohort collects basic patient information, results of diagnostic tests, baseline clinical history,
and data on growth, lung function, microbiology, imaging, clinical manifestations and treatments. Data is
contributed on a standard format that was developed in 2013, in discussion with all contributors. This was
based on the data available in the local datasets and therefore not very detailed. With the standardised
PCD follow-up form (FOLLOW-PCD), the iPCD Cohort now has the possibility to include detailed
physician-reported prospective data and patient-reported information on symptoms, health behaviour and
environmental exposures.
Currently, the iPCD Cohort includes data from 3824 patients from 22 countries in Europe, the
Middle-East, North and South America, and Australia. Each contributor ensures that the delivered data are
pseudo-anonymised and in accordance with the national/local data protection laws. Local principle
investigators are responsible for obtaining local ethical approval and patient informed consent, and the
process is supported by the iPCD Cohort management team. Identifying information linking the data to
the patients is kept by the centre and not included in the iPCD Cohort. Agreements for data delivery and
publication leave all rights with the data contributors. For each planned analysis, eligible data are validated,
cleaned and standardised. So far, the iPCD Cohort has published data on growth, nutrition, lung function
and PCD diagnostics [30–35, 50].
Centres that wish to participate to the iPCD Cohort can contact pcd@ispm.unibe.ch to receive detailed
instructions on how to proceed. Each contributor signs a data delivery agreement and receives a password
to access the online software REDCap to enter data directly [81]. Alternatively, data that are already in the
standard format can be contributed as a data file, e.g. as an export from a national registry or the
International PCD Registry. Centres keep constant access to their datasets and can export them in various
formats for local analyses. Researchers wanting to use the iPCD Cohort dataset can propose a topic and a
concept sheet describing the planned analyses and publication. Participating centres can always decide if
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they want to contribute with their data to a planned analysis and be part of a particular project. Nested
studies using part of the iPCD dataset and collecting additional data are encouraged with methodological
input and support by the iPCD Cohort team. Such data will be added to the iPCD Cohort to enrich it
after each project.
TABLE 4 International PCD (iPCD) Cohort and International PCD Registry: characteristics and methods
iPCD Cohort International PCD Registry
Study design Cohort study, collaborative dataset Registry
Year founded 2013 2014
Inclusion criteria National, collaborative or single-centre datasets of patients
(any age) diagnosed and treated for PCD
National, collaborative or single-centre datasets of patients
(any age) diagnosed and treated for PCD
National legal and ethical requirements met by
participating centre
National legal and ethical requirements met by
participating centre
Both cross-sectional and longitudinal datasets accepted
(longitudinal encouraged)
Patients with probable or confirmed PCD diagnosis who
are treated as PCD in the participating centres, ranging
from clinical presentation consistent with PCD to
diagnosis established with several PCD diagnostic tests
based on the European Respiratory Society diagnostic
recommendations
Patients with a confirmed PCD diagnosis fulfilling the
following diagnostic criteria: clinical presentation
consistent with PCD and consistent findings specific for
PCD by at least two methods (high-frequency video
microscopy analysis, transmission electron microscopy,
immunofluorescence microscopy and low nasal nitric
oxide concentration/production or biallelic disease-
causing mutations by genotyping)
Written informed consent needed for prospective data,
depending on national laws
Entering individual patients requires written informed
consent by the patient or his/her legal guardian(s)
Patients (2019) n 3824 920
Participating
countries
Argentina, Australia, Belgium, Canada, Colombia, Cyprus,
Czech Republic, Denmark, France, Germany, Greece,
Israel, Italy, Netherlands, Norway, Poland, Serbia, Spain,
Switzerland, Turkey, UK, USA
Austria, Belgium, Canada, Cyprus, Denmark, France,
Greece, Germany, Italy, Netherlands, Slovakia, Spain,
Switzerland, Turkey, UK, USA
Prospective/
retrospective
Retrospective and prospective Prospective (and retrospective)
Type of data Pseudo-anonymised Pseudo-anonymised
ClinicalTrials.gov
identifier
NCT03517865 NCT02419365
Database REDCap database Internet-based data entry system; will be transferred to
REDCap October 2019
Easy data import and export in several formats Easy data import and export in several formats
Each collaborator has access to own data Each collaborator has access to own data
Basic data set is monitored for completeness, further
items are currently checked manually for plausibility by
experts
Funding EU-funded BESTCILIA project (FP7/2007–2013) under grant
agreement 305404, Swiss National Science Foundation
320030_173044, Pro-Kartagener Foundation Milena
Karvajal and institutional funding
EU-funded BESTCILIA project (FP7/2007–2013) under grant
agreement 305404, Eva Luise Köhler Research Award,
Care-for-Rare Science Award, REGISTRY WAREHOUSE
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The International PCD Registry
The International PCD Registry, launched in 2014, is governed by a steering committee of the University
Children’s Hospital Muenster (Muenster, Germany) [36]. Since 2019 it has been hosted in the Institute of
Medical Informatics at the University of Muenster. Lately, it has been expanded through the REGISTRY
WAREHOUSE project of the ERN (European Reference Network)-LUNG (https://ern-lung.eu/ern-lung-rd-
registry-data-warehouse). It is now registered with the European Rare Disease Registries Infrastructure
(https://eu-rd-platform.jrc.ec.europa.eu/erdri_en).
The International PCD Registry is designed as a prospective registry, but it is also possible to include
retrospective data. It aims to evaluate clinical presentation, disease course, treatments, outcomes and time
trends, and facilitates recruitment of patients for research studies. Participating centres contribute data
continuously and additional centres can join.
Eligible datasets and collaborating centres were initially identified through the BESTCILIA project and the
BEAT-PCD network. For ERN-LUNG PCD CORE members and associated partners, participation in the
International PCD Registry is mandatory in order to fulfil EU requirements.
The International PCD Registry collects data on diagnostics (high-speed videomicroscopy, transmission
electron microscopy, nasal nitrite oxide, immunofluorescence microscopy and genotype), age and health
status at diagnosis, family history, clinical manifestations, associated malformations/diseases, progression of
the disease, exacerbations, microbiology, lung function, radiological findings, therapeutic measures
(inhalation, antibiotics, oxygen, ventilation, ENT and lung surgery), date and cause of death, fertility, and
quality of life using PCD-specific instruments [57]. For participating centres without access to genetic
testing, this is offered within the framework of research projects.
Currently, the International PCD Registry includes 920 patients from 23 centres in 16 countries in Europe,
the Middle-East, Canada and North America. After written informed consent by the patient or his/her
legal guardian(s), individual patient data can be entered directly. The platform can also integrate data from
local databases, avoiding the need to enter data twice. Informed consent remains with the referring centre
to preserve pseudo-anonymity. Withdrawal of authorisation is possible at any time and all information will
then be destroyed. Healthcare providers can include patients after they obtained local ethical approval.
Publication of the data from individual centres is only possible when the participating centre consents.
Centres that wish to participate in the International PCD Registry need to meet all necessary legal and
ethical requirements. This process is guided by the registry management team. Informed consent forms
and protocols for data collection have been approved by the Ethical Review Committees of the Medical
Council Westfalen-Lippe and the Medical Faculty of the Westphalian Wilhelms University Muenster.
Each referring centre only has access to its own patients’ data. Only the administration team has
insight into data of all patients in an anonymised way. Information linking subject identifier (ID) with
personal data identifying the individual is kept only in the referring centre and is not collected in the
registry. To get access to registry data or recruit participants for research studies the registry steering
committee comprising members of the ERN-LUNG PCD Core group has to be contacted via
PCDRegistry.eu@ukmuenster.de. Planned investigations should be introduced as a short concept sheet,
which will be evaluated by the committee for feasibility and scientific impact. All referring centres will be
asked for approval for utilisation of patient data. For further details, refer to www.pcdregistry.eu or contact
PCDRegistry.eu@ukmuenster.de.
Differences between the iPCD Cohort and the International PCD Registry
Despite their similarities, these two independent initiatives present some important differences. The iPCD
Cohort’s inclusion criteria are broader than those of the International PCD Registry, including also
patients with probable or clinical diagnosis of PCD, which results in a larger number of patients included,
but also in less detailed and standardised data. However, the iPCD Cohort is from its set-up more research
oriented, resulting in many publications. In contrast to the International PCD Registry, patient data are
not always included at regular time intervals, but relevant data are added at irregular intervals, on the
occasion of planned analyses. Lastly, by including more detailed data on diagnostic evaluations, the
International PCD Registry can be used to identify eligible patients for randomised clinical trials studying
specific diagnostic groups.
Data exchange and collaboration
Figure 1 illustrates data flows between national registries, the iPCD Cohort and the International PCD
Registry. All national registries and clinical cohorts described in this review contribute data to the iPCD
Cohort and the International PCD Registry. Some national registries have started to use the standard
clinical form FOLLOW-PCD to collect detailed clinical encounter data. Interested researchers may request
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data from the iPCD Cohort and the International PCD Registry to answer specific questions. Each patient
has a unique iPCD-ID number for the iPCD Cohort as well as the original dataset ID. The iPCD Cohort
and International PCD Registry are independent of each other, but collaborate. As the datasets for the
iPCD Cohort and the International PCD Registry were developed together, many variables are common to
both datasets and have the same format, permitting easy data transfer between the two databases. In
addition, several national registries (e.g. Swiss and Norwegian) have the same format, thus allowing direct
transfer of local data to the iPCD Cohort and the International PCD Registry for specific analyses.
Important findings
National and international studies have helped to characterise disease presentation and course, and to
provide first evidence to guide patient diagnosis and care. Several studies focused on lung function. An
iPCD study including 991 patients found that PCD affects lung function from early in life, comparable to
cystic fibrosis (CF) [32]. Gas exchange [78] and cardiopulmonary fitness seem to be reduced in patients
with PCD, similarly as in CF [39, 49]. Adult patients from France had considerable variability in lung
impairment, usually moderate but more severe in women and patients with chronic infection with
Pseudomonas aeruginosa [21]. Patients from Cyprus diagnosed late in adulthood had advanced lung
disease and prior lobectomy was a poor prognostic factor for the disease course [51]. Longitudinal studies
in children and young adults reported stable spirometry but slight increases in the lung clearance index in
children and young adults with PCD [40, 48]. There is increasing evidence that lung function is associated
with the type of ultrastructural defect [32, 74]. Mannose-binding leptin (MBL) deficiency was associated
with steeper lung function decline in Danish PCD patients, suggesting that the MBL phenotype might be a
disease modifier in PCD [82].
Growth and nutrition in PCD patients can be impaired from early childhood, and are strongly associated
with lung function [30]. A study in the UK suggests that childhood monitoring of nutritional status and
vitamin D levels could help to identify children at risk who would require nutritional support [63]. Data
on upper airways from France suggest that adult patients commonly suffer from rhinosinusitis but less
frequently from otitis media with effusion. The latter was associated with a worse lung function [77].
Studies from the Danish registry found simultaneous sinus and lung infections with the same bacterium [47],
and improvements in chronic rhinosinusitis symptoms and lung function after sinus surgery [46]. Only
few studies focused on non-respiratory manifestations such as infertility, situs defects and congenital heart
disease [9, 58].
Discussion
This article gives an overview of the European registries and collaborative studies for PCD. While a decade
ago clinical research in PCD relied on small cross-sectional studies and case series, with information
assessed at one time-point or from retrospective charts reviews, we now have large population-based
registries and collaborative studies in Europe. This allows us to tackle open questions using standardised
representative and prospective datasets.
Population-based national registries aim to include every patient with PCD in a country, allowing us to
assess incidence and prevalence, and to describe the full range of clinical presentation and prognosis. The
summaries presented review the current state of the registries and problems they have to overcome.
Registries are easier to lead in countries with centralised care, such as Cyprus or Denmark with only one
national PCD centre. In such a system, every resident diagnosed with PCD has a record in one of the
dedicated clinics and a clinical registry is automatically completed. In countries with decentralised care,
such as Switzerland, patients are seen in numerous clinics and private practices, and registries must
actively search for new patients by regularly contacting all medical specialists likely to see PCD patients
(pulmonologists, ENT physicians, cardiologists, neonatologists and fertility specialists) and patient
networks, which leads to high costs. Other countries with decentralised care, such as Norway, follow-up all
known PCD patients at least annually in one centralised clinic using a shared-care strategy.
Prevalence data (table 2) suggest, however, that only a fraction of adult patients are diagnosed and thus
included in registries [53]. For children and adolescents aged 0–19 years, estimated prevalence was 7 per
100000 in Cyprus and 3–5 per 100000 in Norway, Denmark and Switzerland. Considering late diagnosis
in children with less severe presentation, these data support the estimate that PCD affects about 1 per
10 000 people. Prevalence of PCD in adults is much lower in all registries, around 0.2–2 per 100000 in
Norway and Switzerland, and up to 4–6 per 100000 in Cyprus and Denmark, where single national PCD
centres exist. Although life expectancy in PCD might be slightly reduced, this does not explain the
prevalence gap between children and adults [15]. The likely explanation is a considerable underdiagnosis
of PCD in adults that are treated under wide diagnostic “umbrellas”, e.g. non-CF bronchiectasis, and
missing registration. The lack of funding to reimburse centres or doctors for data entry into national
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registries (from where international collaborations obtain their data too) may also reduce data collection
completeness, especially in adults. This does not only lead to low precision of results for adult patients, e.g.
on lung function [30, 32, 36], but also to biased and potentially wrong results. It is impossible to know
whether registered adult patients represent the average patient, or rather the upper or lower end of the
severity spectrum. Although numbers are rising and there are initiatives such as the ERS Task Force
registry EMBARC (www.bronchiectasis.eu) and the UK Bronch-UK (www.bronch.ac.uk), adult
pulmonologists remain massively under-represented in PCD task forces and networks. This will hopefully
change with the establishment of PCD excellence centres for adults in the UK and elsewhere.
Two large collaborative studies, the iPCD Cohort and the International PCD Registry, combine data from
registries and single-centre studies from Europe and beyond into large research datasets with sufficient
statistical power and precision for different types of analyses. Both initiatives have key strengths that
provide opportunities for different types of research. The iPCD Cohort includes more patients (nearly
4000), as it also includes older datasets. The International PCD Registry is smaller, but growing, and has
potential as it now receives continuous support from the EU in the ERN-LUNG network. It contains
detailed data on results from diagnostic evaluations, particularly genetics, and will allow genotype–
phenotype association studies to be performed in the future. Both the iPCD Cohort and the International
PCD Registry collect a minimal core dataset of clinical information. This can be overcome by focused
collection of additional data in nested studies, which can be fed back to the original dataset to enrich it
further. This approach has worked well for the iPCD Cohort where some national registries register data
in iPCD continuously, while others contribute tailored datasets for specific analyses and publications. The
introduction of FOLLOW-PCD, a standardised form for collecting data during routine care, will greatly
improve the richness of the dataset.
Outside Europe, there are other established or emerging studies on patients with PCD. An important
resource is the PCD Foundation Clinical and Research Centers Network in North America, which has
recently set up the PCD Foundation Registry collecting health and demographic data of PCD patients who
are followed in the participating centres (https://pcdfoundation.org/registry). In Australia, a clinical care
and research network has been developed between Sydney and Melbourne [83, 84], and Japan has recently
conducted a nationwide survey of PCD patients as a first step towards the development of a national
registry [85].
Similar efforts in other rare diseases have paved the way for significant advances in the epidemiological
and clinical knowledge on rare diseases. Examples in pulmonary medicine include registries for CF [86, 87],
non-CF bronchiectasis [88], interstitial lung disease [89], α1-antitrypsin deficiency [90] and pulmonary
hypertension [91]. ERN-LUNG (https://ern-lung.eu), the Network of European Healthcare Providers
dedicated to care and research for patients with rare respiratory diseases, will provide further means and
platforms to coordinate and standardise care for rare lung diseases, and provides funds for the
International PCD Registry.
The most advanced and best-know examples of registries for rare diseases are cancer registries [92]. A
systematic registration of cancer (many of which are rare, including all childhood cancers) was set up in
the 1950s by pioneer countries (e.g. the Nordic countries and the UK) and has expanded since then;
coverage is now almost universal. Cancer registries include large numbers of patients and thus usually
collect a limited dataset. Completeness of case registration is usually high (over 95% of affected patients),
and therefore provides reliable data on incidence and survival. Time trends and regional differences in
incidence allow us to investigate potential causes of cancer, while survival differences can be used to
investigate differences in healthcare between countries. Cancer registries also serve as sampling frames to
recruit patients into randomised clinical studies, which compare new treatment options with the current
standards of care [93]. The routine of including a large number of patients into clinical trials led to
continuous improvements in childhood cancer survival, with a cure rate of over 85% [94, 95]. Such rapid
improvements in outcomes have hardly been reached in other rare diseases, where patients are not cared
for centrally, not reported to registries and not routinely included in trials. Exact residential addresses in
cancer registries have allowed investigation into environmental risk factors for cancer incidence comparing
geographically and varying environmental exposures (such as ionising radiation or air pollution) [96, 97].
Lastly, cancer registries have served as baselines for lifelong follow-up studies on long-term morbidity,
mortality and quality of life, permitting us to study long-term toxicities of specific treatment modalities,
and to adapt treatment of new patients to optimise cure rates while minimising long-term side-effects [98].
Funding is a continuous problem for rare disease registries, as money is scarce and patients are scattered.
The longer history and the population-based setting of cancer registries allowed them to develop efficient
and cheap ways of data collection. While most pulmonary registries still rely on manual data entry by
physicians and active follow-up of individual patients for vital status, cancer registries have developed
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more efficient routines. Importantly, they often operate without collecting informed consent, which is time
consuming and expensive, but based on a legislation that provides for ample information of patients and
the right to opt out, rather than to opt in. Data collection is as automatic as possible, with pathology
laboratory and hospital statistics automatically delivering cancer diagnoses to registries, and survival and
causes of death being ascertained via data linkage with national mortality records. This leads to cheaper,
more complete and more sustainable ways of data collection, which could also easily be adopted by other
registries. Lastly, the recent developments facilitating the automated use of the data contained in hospital
information systems should be used for rare diseases [99, 100]. However, this is dependent on national
legislation and needs strong protection data measures, as many rare diseases are genetic.
In summary, while a decade ago clinical data on patients with PCD were available only from small
cross-sectional studies of selected patients, we now have a valuable and fast-expanding network of national
population-based registries and collaborative studies. The registries may be further improved if they are
standardised, with more efficient data collection and data sharing, improve data quality, use information
that is routinely collected during healthcare and are able to analyse the data quickly, ideally in real-time.
These datasets have a huge potential to help answer many open questions in the clinical epidemiology of
PCD and serve to provide continuous evidence-based improvements in care and quality of life of affected
patients.
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